| Officer | Age | Joined | 2025 pay | Source |
|---|---|---|---|---|
|
Alexander Hardy
Also a director
President and Chief Executive Officer
|
57 | Not stated | $21,927,563 | |
|
Brian R. Mueller
Executive Vice President and Chief Financial Officer
|
52 | 2002 | $6,831,812 | |
|
G. Eric Davis
Executive Vice President, Chief Legal Officer and Secretary
|
55 | 2004 | Not reported | |
|
Gregory R. Friberg
EVP, Chief R&D Officer
Title from the Form 4 dated Sep 30, 2026
|
52 | Not stated | $7,174,583 | |
|
C. Greg Guyer
Executive Vice President and Chief Technical Officer
|
64 | Not stated | $5,691,680 | |
|
Cristin Hubbard
Executive Vice President and Chief Commercial Officer
|
50 | Not stated | $5,713,695 | |
|
Rashmi Ramchandani
Vice President and Chief Accounting Officer
|
47 | Not stated | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Apr 21, 2026 · updated by the 8-K of Sep 14, 2026
| Director | Age | On board | Independent | Committees | Other public boards | 2025 pay | Source |
|---|---|---|---|---|---|---|---|
|
Ian T. Clark
Board chair
|
65 |
2025
1 year
|
Independent | None stated | None stated | $451,230 | |
|
Alexander Hardy
CEO
|
57 |
2023
3 years
|
Not independent | None stated | None stated | Paid as CEO | |
|
Elizabeth McKee Anderson
|
68 |
2019
7 years
|
Independent |
Compensation Committee · Chair
|
GSK plc, Insmed, Inc., Revolution Medicines, Inc. | $505,035 | |
|
Barbara W. Bodem
|
58 |
2023
3 years
|
Independent | None stated | Enovis Corp., Option Care Health, Inc. | $487,035 | |
|
Athena Countouriotis
|
54 |
2023
3 years
|
Independent | None stated | Iovance Biotherapeutics, Inc. | $493,660 | |
|
Willard Dere
|
72 |
2016
10 years
|
Independent |
Science and Technology Committee · Chair
|
Seres Therapeutics, Inc., Metagenomi, Inc. | $509,035 | |
|
Mark J. Enyedy
|
62 |
2023
3 years
|
Independent |
CGN Committee · Chair
|
Charles River Laboratories International, Inc. | $501,285 | |
|
Maykin Ho
|
73 |
2021
5 years
|
Independent | None stated | Agios Pharmaceuticals Inc., Kyntra Bio, Inc., Neumora Therapeutics, Inc. | Not stated | |
|
Robert J. Hombach
|
60 |
2017
9 years
|
Independent |
Audit Committee · Chair
|
Embecta Corporation | $509,535 | |
|
Timothy P. Walbert
|
59 |
2025
1 year
|
Independent | None stated | Mirum Pharmaceuticals, Inc., Century Therapeutics, Inc., Sagimet Biosciences Inc. | $492,785 | |
|
Robert Plenge
Joined Sep 10, 2026
|
- | - | Independent |
Science and Technology Committee
|
- | - | |
|
Meier
Leaving at the meeting
|
Not stated | Not stated | Independent | None stated | None stated | Not stated |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
The proxy filed Apr 21, 2026 states there were none.
Read it in the proxyLoading...